Dexcom Q3 profit surges as CGM maker prepares for G7 launch in U.S. was reported by Elise Reuter for, 28 October 2022. The company expects to begin selling its newest continuous glucose monitor in the first quarter of 2023 if it receives FDA approval this year.

Dexcom reported another quarter of double-digit revenue growth, driven by new customers using its continuous glucose monitors (CGMs). The San Diego-based firm’s revenue increased 17% in the U.S., while international revenue rose 22%. The company recently launched its newest device, the G7 CGM, in Europe, as it awaits approval from the Food and Drug Administration in the U.S. It’s also preparing for an expansion of eligible patients, as the Centers for Medicare and Medicaid Services has proposed new guidelines that could result in the devices being covered for more patients with Type 1 and Type 2 diabetes.

“We have learned in our U.S. markets, getting access and getting reimbursement through these government agencies is absolutely critical and key to driving growth,” CEO Kevin Sayer said in an earnings call on Thursday. “We’re getting access to more people who can use our technology and use our better product. For right now, we haven’t seen any macro trends that would make us feel that this isn’t going to continue. As we get more access, we will continue to grow and do well.”

G7 timing: Dexcom said in the last quarter that FDA approval of its G7 CGM would be delayed until late 2022 as the company needed to update the device’s software after questions arose during the agency’s review. In Thursday’s call, the CEO reaffirmed that timing, saying Dexcom is “feeling really good about this being the end of the review period” and planning a full launch of the product for the first quarter of 2023. 

Read more:   Dexcom Q3 profit surges as CGM maker prepares for G7 launch in U.S.

New islet transplant method leads to insulin independence was posted by the Perelman School of Medicine of the University of Pennsylvania, 17 October 2022.  

A pancreatic islet from a mouse in a typical position, close to a blood vessel; insulin in red, nuclei in blue.

More than half of the most seriously affected type 1 diabetes patients achieved years of insulin independence after they received a new method of islet cell transplantation, according to a paper published in Diabetes Care on the long-term outcomes of two Phase 3 clinical trials.

In addition to finding that many patients didn’t need insulin to maintain their blood sugar for up to eight years, the authors, co-led by Michael Rickels, MD, the Willard, and Rhoda Ware Professor in Diabetes and Metabolic Diseases in the Perelman School of Medicine at the University of Pennsylvania, also reported that the new approach necessitated fewer transplants than typical and was exceedingly safe.

“These data are important in showing that in the long run, islet transplantation has efficacy, including among those who have had kidney transplants,” said Rickels. “Yes, most type 1 diabetes patients are improved tremendously with current insulin delivery systems. But for those having the most difficulty controlling their blood sugar, and those whose diabetes has already been complicated by needing a kidney transplant, the outcomes we saw in this study are what we’ve been hoping to achieve for more than 20 years.”

Almonds can help support the gut microbiome was written by Robby Berman for, 29 October 2022.  

A new study finds that eating 56 grams of almonds daily — the equivalent of approximately 46 almonds — can improve gut health by promoting levels of butyrate. The research involved three groups replacing their regular snacks with whole almonds, ground almonds, or an energy-equivalent control muffin.  The authors conclude that incorporating almonds into the diet could be a way of increasing fiber intake without triggering gut symptoms.

An important player in gut health appears to be butyrate, a short-chain fatty acid that supports the health of the microbiome itself.  “Butyrate is important to gut health, as it acts as the primary source of fuel for the cells of the colon, allowing them to function correctly and optimally. It is also involved in signaling to the gut to initiate the process of nutrient absorption.”

“In addition,” said Dr. Alice Creedon (a postdoctoral researcher in the Department of Nutritional Studies at King’s College London and the first author of a new study exploring the value of almonds as a means of supporting the microbiome’s supply of butyrate), “butyrate produced in the gut can enter the bloodstream where it is involved in the regulation of health in other areas of the body, such as the liver, brain, and lungs.”  The study, which demonstrates that eating a healthy handful of almonds each day promotes the production of butyrate, appears in The American Journal of Clinical Nutrition. The research was funded by the Almond Board of California.

Uh oh … funded by the Almond Board of California??? Do you trust these results?  

Read more:  Almonds can help support the gut microbiome

Graduate of Eman Schools in Fishers (Indiana, US) awarded prestigious scholarship was published by YouAre, 17 October 2022.  

Safiya Sankari, a 2021 graduate of Eman Schools in Fishers, has received the Rise Global Winners scholarship for her research and development of an algorithm that turns breath vapors into glucose readings for diabetic patients. The opportunity provides Sankari full tuition for her entire four years at MIT in Boston, Mass., along with other lifetime benefits. After being accepted to her dream school, Sankari took a gap year to pursue her own research opportunities. During that year, she created the algorithm that qualified her for the Rise scholarship while working in Dr. Mangilal Agarwal’s lab at IUPUI. Sankari’s research was presented in August at the National Chemical Society Conference in Chicago.

This should be interesting to watch … possibly a non-invasive method for measuring glucose readings from breath!

Read more:  Fishers graduate awarded with prestigious scholarship



Share This
Skip to content